Tiragolumab (Anti-TIGIT)用于SCLC: Skyscraper-02，一个高耸的地狱。

IF 5.1 Q1 ONCOLOGY

Lung Cancer: Targets and Therapy Pub Date : 2023-01-01 DOI:10.2147/LCTT.S379389

Danielle Brazel, Sai-Hong Ignatius Ou, Misako Nagasaka

{"title":"Tiragolumab (Anti-TIGIT)用于SCLC: Skyscraper-02，一个高耸的地狱。","authors":"Danielle Brazel, Sai-Hong Ignatius Ou, Misako Nagasaka","doi":"10.2147/LCTT.S379389","DOIUrl":null,"url":null,"abstract":"Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when tiragolumab was added to atezolizumab and chemotherapy, the phase III SKYSCRAPER-02 failed to find PFS or OS benefit in patients with SCLC. Atezolizumab was the first immunotherapy to show survival benefit in extensive SCLC based on the phase III IMpower133 study. Given that immunotherapy has become the standard of care for SCLC patients, further research is needed into ways to augment the immune system to better treat these patients.","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":5.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/bc/lctt-14-1.PMC9831070.pdf","citationCount":"7","resultStr":"{\"title\":\"Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno.\",\"authors\":\"Danielle Brazel, Sai-Hong Ignatius Ou, Misako Nagasaka\",\"doi\":\"10.2147/LCTT.S379389\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when tiragolumab was added to atezolizumab and chemotherapy, the phase III SKYSCRAPER-02 failed to find PFS or OS benefit in patients with SCLC. Atezolizumab was the first immunotherapy to show survival benefit in extensive SCLC based on the phase III IMpower133 study. Given that immunotherapy has become the standard of care for SCLC patients, further research is needed into ways to augment the immune system to better treat these patients.\",\"PeriodicalId\":18066,\"journal\":{\"name\":\"Lung Cancer: Targets and Therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/bc/lctt-14-1.PMC9831070.pdf\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer: Targets and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/LCTT.S379389\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer: Targets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/LCTT.S379389","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 7

摘要

小细胞肺癌(SCLC)的特点是进展快，预后差。尽管II期CITYSCAPE-02试验发现，当替拉单抗加入阿特唑单抗和化疗时，非小细胞肺癌(NSCLC)患者的客观缓解率(ORR)和无进展生存期(PFS)得到改善，但III期SKYSCRAPER-02试验未能发现SCLC患者的PFS或OS获益。基于III期IMpower133研究，Atezolizumab是首个显示广泛SCLC生存获益的免疫疗法。鉴于免疫治疗已成为SCLC患者的标准治疗，需要进一步研究增强免疫系统的方法以更好地治疗这些患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno.

Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when tiragolumab was added to atezolizumab and chemotherapy, the phase III SKYSCRAPER-02 failed to find PFS or OS benefit in patients with SCLC. Atezolizumab was the first immunotherapy to show survival benefit in extensive SCLC based on the phase III IMpower133 study. Given that immunotherapy has become the standard of care for SCLC patients, further research is needed into ways to augment the immune system to better treat these patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lung Cancer: Targets and Therapy Medicine-Oncology

CiteScore

8.10

自引率

0.00%

发文量

审稿时长

16 weeks